Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 8/20 | 0.79 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.79 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 13/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4042806 | 0.98 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL5259750 | 0.92 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL5258210 | 0.91 | CYP2C9 (0.75) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL5256225 | 0.91 | PDE4A (0.96) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL5256891 | 0.90 | CYP2C9 (0.73) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4204741 | 0.89 | CYP2C9 (0.87) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4211926 | 0.89 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4207515 | 0.88 | CYP2C9 (0.85) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4038639 | 0.87 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL5256208 | 0.87 | CYP2C9 (0.72) | PDE4APDE4BPDE4CPDE4DCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517895-B1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2007-03-14 | — | — | EP | claimed |
| US-7153968-B2 | 8-(biaryl)quinoline PDE4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2006-12-26 | — | — | US | claimed |
| US-20050234238-A1 | 8-(Biaryl)quinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-10-20 | — | — | US | claimed |
| EP-1517895-B1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234238-A1 | 8-(Biaryl)quinoline pde4 inhibitors | IL4, PDE4A, PDE4C | PDE4A 2/4885PDE4B 5/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.